Hyaluronan Inhibition as a Therapeutic Target for Diabetic Kidney Disease: What Is Next?

被引:1
|
作者
Salman, Loay [1 ,4 ]
Martinez, Laisel [2 ]
Faddoul, Geovani [1 ]
Manning, Christina [1 ]
Ali, Karim [1 ]
Salman, Maya [3 ]
Vazquez-Padron, Roberto [2 ]
机构
[1] Albany Med Hlth Syst, Dept Med, Div Nephrol & Hypertens, Albany, NY USA
[2] Univ Miami, Leonard M Miller Sch Med, DeWitt Daughtry Family Dept Surg, Div Vasc Surg, Miami, FL USA
[3] Damascus Univ, Fac Med, Damascus, Syria
[4] Albany Med Hlth Syst, Div Nephrol & Hypertens, 25 Hackett Blvd,MC 69, Albany, NY 12208 USA
来源
KIDNEY360 | 2023年 / 4卷 / 06期
关键词
diabetic kidney disease (DKD); CKD; 4-methylumbelliferone (4-MU); hyaluronan (HA); hymecromone; 4-methylumbelliferyl glucuronide (4-MUG); 4-methylumbelliferyl sulfate (4-MUS); GLOMERULAR-FILTRATION-RATE; GROWTH-FACTOR-BETA; IMPAIRED AUTOREGULATION; CARDIOVASCULAR OUTCOMES; BLOOD-FLOW; HYMECROMONE; NEPHROPATHY; RISK; ACID; EXPRESSION;
D O I
10.34067/KID.0000000000000126
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Diabetic kidney disease (DKD) is the leading cause of CKD and ESKD in the United States and worldwide. Pharmacotherapy and lifestyle modifications for glycemia, dyslipidemia, and BP control have shown success in slowing the progression of DKD. Traditional treatments, such as angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and more recently the use of sodium-glucose cotransporter 2 inhibitors, nonsteroidal selective mineralocorticoid receptor antagonists, such as finerenone, and glucagon-like peptide 1 receptor agonists, have led to added benefits on various outcomes. However, significant residual risk for DKD progression remains despite the current standard-of-care approaches. Arteriolar hyalinosis (AH) is among the key findings seen on kidney biopsies of patients with DKD. It results from the excessive accumulation of hyaluronan (HA) in the arterioles. AH has not been targeted specifically by any of the therapeutic methods currently being used. We discuss in this manuscript the potential use of a selective therapy targeting AH and the increased total renal HA deposits using a HA synthesis inhibitor in DKD.
引用
收藏
页码:851 / 860
页数:10
相关论文
共 50 条
  • [1] Complement, a Therapeutic Target in Diabetic Kidney Disease
    Budge, Kelly
    Dellepiane, Sergio
    Yu, Samuel Mon-Wei
    Cravedi, Paolo
    FRONTIERS IN MEDICINE, 2021, 7
  • [2] Diabetic kidney disease: what does the next era hold?
    不详
    LANCET DIABETES & ENDOCRINOLOGY, 2015, 3 (09): : 665 - 665
  • [3] Metabolic reprogramming: A novel therapeutic target in diabetic kidney disease
    Wang, Mengdi
    Pang, Yanyu
    Guo, Yifan
    Tian, Lei
    Liu, Yufei
    Shen, Cun
    Liu, Mengchao
    Meng, Yuan
    Cai, Zhen
    Wang, Yuefen
    Zhao, Wenjing
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [4] Histone demethylase UTX is a therapeutic target for diabetic kidney disease
    Chen, Hong
    Huang, Yixue
    Zhu, Xiuqin
    Liu, Chong
    Yuan, Yangmian
    Su, Hua
    Zhang, Chun
    Liu, Chengyu
    Xiong, Mingrui
    Qu, Yannan
    Yun, Peng
    Zheng, Ling
    Huang, Kun
    JOURNAL OF PHYSIOLOGY-LONDON, 2019, 597 (06): : 1643 - 1660
  • [5] Complement anaphylatoxins: Potential therapeutic target for diabetic kidney disease
    Ma, Jingyuan
    Yiu, Wai Han
    Tang, Sydney C. W.
    DIABETIC MEDICINE, 2025, 42 (02)
  • [6] What is the role of renin inhibition in the treatment of diabetic kidney disease?
    Radko Komers
    Current Diabetes Reports, 2009, 9 : 447 - 452
  • [7] What is the role of renin inhibition in the treatment of diabetic kidney disease?
    Komers, Radko
    CURRENT DIABETES REPORTS, 2009, 9 (06) : 447 - 452
  • [8] Nox5: a promising therapeutic target for diabetic kidney disease
    Jha, J. C.
    Dai, A.
    Kankanamalage, H. R.
    Meister, J.
    Vincent, J.
    Cooper, M. E.
    Jandeleit-Dahm, K.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S71 - S71
  • [9] Could renin inhibition be the next step forward in the treatment of diabetic kidney disease?
    Tuttle, Katherine R.
    NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM, 2009, 5 (01): : 20 - 21
  • [10] Could renin inhibition be the next step forward in the treatment of diabetic kidney disease?
    Katherine R Tuttle
    Nature Clinical Practice Endocrinology & Metabolism, 2009, 5 : 20 - 21